1Iwama A,Yoshida, Miwa A,et al. Improved survival from fungaemia in patients with haematological malignancies: Analysis of risk factors for death and usefulness of early antifungal theraphy[J]. Eur J Haematol,1993,51,156-160
2Bodey G,Bueltmann B,Duguid W,et al. Fungal infection in cancer patients: an international autopsy survery [J]. Eur J Clin Microbiol Infect Dis, 1992,11,99-109.
3Funai N,Shimamoto Y,Tokunaga O,et al. Ten-year survey of incidence of infection as a cause of death in hematologic malignancies: study of 90 autopsied case [J]. Acta Hematol, 1995,93: 25-30.
4Sabah Sallah, Richard C, Semelka, et al. Amphotericin B Lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis[J]. Leukemia Research, 1999,23: 995-999.
5Smith KK, Quadri SMH. Rapid diagnosis of systemic candiasis using commercial antigen and antibody detection kits[J] .J Microbiol Methods, 1992,16: 231-237.
6Ruchel R.Diagnosis if invasive mycoses in severely immunosuppressed patients[J]. Ann Hematol, 1993,67:1.
7Stynen D,Goris A,Sarfati J,et al.A sensitive sandwich enzyme-linked immnosorbent assay to detect galatofuran in patients with invasive aspergillosis[J] .J Clin Microbiol, 1995,33(2) ;497-500.
8Meunier F, Aoun M, Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: A randomized doublize-blind study of fluconazole vs ketoconazole[J] .Rev Infect Dis, 1990,12(Suppl3) :364-368.
9Prontice AG, Bradford GR. Prophylaxis of fungal infections with itroconazle during remission- induction therapy[J]. Mycoses, 1989,32 ( Supp1l) :96-102.
10Alison G, Freifield. The antimicrobial armamantarium[J]. Henatol Oncat Clin North Am. 1993,7(4) :813-839.
4Barbaric D,Shaw PJ.Scedosporium infection in immunocompromised patients:successful use of liposomal amphotericin B and itraconazole.Med Pediatr Oncol,2001,37(2):122
5Herbrecht R.Voriconazole:therapeutic review of a new azole antifungal.Expert Rev Anti Infect Ther,2004,2(4):485
